Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 47,151	$ 73,286
Short-term restricted cash	703	45
Marketable securities		4,385
Prepaid expenses and other current assets	4,483	3,373
Refundable tax credit	1,315	2,333
Total current assets	53,652	83,422
Long-term restricted cash	494	439
Operating lease right-of-use assets	3,568
Other assets	765	213
Total assets	58,479	84,074
Current liabilities:
Current portion of debt	197	189
Accounts payable	2,691	1,998
Accrued expenses	5,776	7,630
Operating lease liabilities — current	1,849
Total current liabilities	10,513	9,817
Debt, net of current portion	218	383
Operating lease liabilities	2,690
Other liabilities	229	752
Total liabilities	13,650	10,952
Commitments and contingencies (Note 6)
Stockholders' equity:
Preferred stock, $0.001 par value: 5,000,000 shares authorized; no shares issued and outstanding
Common stock, $0.001 par value: 100,000,000 shares authorized; 13,472,937 and 13,357,999 shares issued and outstanding at September 30, 2019 and December 31, 2018, respectively	13	13
Additional paid-in capital	238,893	234,876
Accumulated deficit	(195,955)	(164,086)
Accumulated other comprehensive income	123	148
Total stockholders’ equity attributable to Millendo Therapeutics, Inc.	43,074	70,951
Equity attributable to noncontrolling interests	1,755	2,171
Total stockholders' equity	44,829	73,122
Total liabilities and stockholders' equity	$ 58,479	$ 84,074